Latest & greatest articles for levothyroxine

The Trip Database is a leading resource to help health professionals find trustworthy answers to their clinical questions. Users can access the latest research evidence and guidance to answer their clinical questions. We have a large collection of systematic reviews, clinical guidelines, regulatory guidance, clinical trials and many other forms of evidence. If you wanted the latest trusted evidence on levothyroxine or other clinical topics then use Trip today.

This page lists the very latest high quality evidence on levothyroxine and also the most popular articles. Popularity measured by the number of times the articles have been clicked on by fellow users in the last twelve months.

What is Trip?

Trip is a clinical search engine designed to allow users to quickly and easily find and use high-quality research evidence to support their practice and/or care.

Trip has been online since 1997 and in that time has developed into the internet’s premier source of evidence-based content. Our motto is ‘Find evidence fast’ and this is something we aim to deliver for every single search.

As well as research evidence we also allow clinicians to search across other content types including images, videos, patient information leaflets, educational courses and news.

For further information on Trip click on any of the questions/sections on the left-hand side of this page. But if you still have questions please contact us via jon.brassey@tripdatabase.com

Top results for levothyroxine

1. Treatment of hypothyroidism with levothyroxine plus liothyronine: a randomized, double-blind, crossover study. (PubMed)

Treatment of hypothyroidism with levothyroxine plus liothyronine: a randomized, double-blind, crossover study. To compare the effects of a unique fixed combination levothyroxine/liothyronine (LT4/LT3) therapy in patients with primary hypothyroidism.This is a randomized, double-blind, crossover study. Adults with primary hypothyroidism (n = 32, age 42.6 ± 13.3, 30 females) on stable doses of LT4 for ≥ 6 months (125 or 150 μg/day) were randomized to continue LT4 treatment (G1) or to start LT4/LT3

Full Text available with Trip Pro

2016 Archives of endocrinology and metabolism

2. Randomised controlled trial: Second trimester levothyroxine treatment for subclinical hypothyroidism or hypothyroxinaemia of pregnancy does not improve cognitive outcomes of children

Randomised controlled trial: Second trimester levothyroxine treatment for subclinical hypothyroidism or hypothyroxinaemia of pregnancy does not improve cognitive outcomes of children Second trimester levothyroxine treatment for subclinical hypothyroidism or hypothyroxinaemia of pregnancy does not improve cognitive outcomes of children | BMJ Evidence-Based Medicine We use cookies to improve our service and to tailor our content and advertising to you. You can manage your cookie settings via your (...) browser at any time. To learn more about how we use cookies, please see our . Log in using your username and password For personal accounts OR managers of institutional accounts Username * Password * your user name or password? Search for this keyword Search for this keyword Main menu Log in using your username and password For personal accounts OR managers of institutional accounts Username * Password * your user name or password? You are here Second trimester levothyroxine treatment for subclinical

2017 Evidence-Based Medicine (Requires free registration)

3. Current evidence for the treatment of hypothyroidism with levothyroxine/levotriiodothyronine combination therapy versus levothyroxine monotherapy. (PubMed)

Current evidence for the treatment of hypothyroidism with levothyroxine/levotriiodothyronine combination therapy versus levothyroxine monotherapy. Hypothyroidism is relatively common, occurring in approximately 5% of the general US population aged ≥12 years. Levothyroxine (LT4) monotherapy is the standard of care. Approximately, 5%-10% of patients who normalise thyroid-stimulating hormone levels with LT4 monotherapy may have persistent symptoms that patients and clinicians may attribute

Full Text available with Trip Pro

2018 International journal of clinical practice

4. Reduction of thyroid nodule volume by levothyroxine and iodine alone and in combination: a randomized, placebo-controlled trial. (PubMed)

Reduction of thyroid nodule volume by levothyroxine and iodine alone and in combination: a randomized, placebo-controlled trial. Nodular goiter is common worldwide, but there is still debate over the medical treatment.The objective of the study was the measurement of the effect of a treatment with (nonsuppressive) T(4), iodine, or a combination of both compared with placebo on volume of thyroid nodules and thyroid.This was a multicenter, randomized, double-blind trial in patients with nodular (...) goiter in Germany [LISA (Levothyroxin und Iodid in der Strumatherapie Als Mono-oder Kombinationstherapie) trial].The study was conducted in outpatient clinics in university hospitals and regional hospitals and private practices.One thousand twenty-four consecutively screened and centrally randomized euthyroid patients aged 18-65 yr with one or more thyroid nodules (minimal diameter 10 mm) participated in the study.Intervention included placebo, iodine (I), T(4), or T(4)+I for 1 yr. T(4) doses were

Full Text available with Trip Pro

2011 The Journal of clinical endocrinology and metabolism

5. Depressive symptoms in patients with subclinical hypothyroidism - the effect of treatment with levothyroxine: a double-blind randomized clinical trial. (PubMed)

Depressive symptoms in patients with subclinical hypothyroidism - the effect of treatment with levothyroxine: a double-blind randomized clinical trial. Despite the increasing evidence for relationships between thyroid dysfunction and neuropsychiatric alterations, the effect of treatment of thyroid disease on various clinical psychiatric outcomes is controversial. The purpose of this study was to investigate the effect of levothyroxine treatment on depressive symptoms in subjects (...) with subclinical hypothyroidism. A randomized double-blind placebo-controlled clinical trial was performed. Sixty subjects (51 females and 9 males) with subclinical hypothyroidism were enrolled. Beck Depression Inventory was completed for all participants at the beginning of the study and 12 weeks after enrollment. The intervention and control groups received levothyroxine and placebo, respectively, for 12 weeks. There were no statistical differences in the total depression score and its subscales between

2015 Endocrine research

6. Desiccated Thyroid Extract and Levothyroxine for Hypothyroidism Treatment

Desiccated Thyroid Extract and Levothyroxine for Hypothyroidism Treatment Desiccated Thyroid Extract and Levothyroxine for Hypothyroidism Treatment - Full Text View - ClinicalTrials.gov Hide glossary Glossary Study record managers: refer to the if submitting registration or results information. Search for terms x × Study Record Detail Saved Studies Save this study Warning You have reached the maximum number of saved studies (100). Please remove one or more studies before adding more. Desiccated (...) Thyroid Extract and Levothyroxine for Hypothyroidism Treatment (DTE) The safety and scientific validity of this study is the responsibility of the study sponsor and investigators. Listing a study does not mean it has been evaluated by the U.S. Federal Government. Read our for details. ClinicalTrials.gov Identifier: NCT01739972 Recruitment Status : Unknown Verified November 2012 by Mohamed K.M. Shakir, Walter Reed National Military Medical Center. Recruitment status was: Recruiting First Posted

2012 Clinical Trials

7. Study protocol: a randomised controlled trial on the clinical effects of levothyroxine treatment for subclinical hypothyroidism in people aged 80 years and over. (PubMed)

Study protocol: a randomised controlled trial on the clinical effects of levothyroxine treatment for subclinical hypothyroidism in people aged 80 years and over. Subclinical hypothyroidism is common in older people and its contribution to health and disease needs to be elucidated further. Observational and clinical trial data on the clinical effects of subclinical hypothyroidism in persons aged 80 years and over is inconclusive, with some studies suggesting harm and some suggesting benefits (...) , translating into equipoise whether levothyroxine therapy provides clinical benefits. This manuscript describes the study protocol for the Institute for Evidence-Based Medicine in Old Age (IEMO) 80-plus thyroid trial to generate the necessary evidence base.The IEMO 80-plus thyroid trial was explicitly designed as an ancillary experiment to the Thyroid hormone Replacement for Untreated older adults with Subclinical hypothyroidism randomised placebo controlled Trial (TRUST) with a near identical protocol

Full Text available with Trip Pro

2018 BMC Endocrine Disorders

8. Effects of evening vs morning levothyroxine intake: a randomized double-blind crossover trial. (PubMed)

Effects of evening vs morning levothyroxine intake: a randomized double-blind crossover trial. Levothyroxine sodium is widely prescribed to treat primary hypothyroidism. There is consensus that levothyroxine should be taken in the morning on an empty stomach. A pilot study showed that levothyroxine intake at bedtime significantly decreased thyrotropin levels and increased free thyroxine and total triiodothyronine levels. To date, no large randomized trial investigating the best time (...) of levothyroxine intake, including quality-of-life evaluation, has been performed.To ascertain if levothyroxine intake at bedtime instead of in the morning improves thyroid hormone levels, a randomized double-blind crossover trial was performed between April 1, 2007, and November 30, 2008, among 105 consecutive patients with primary hypothyroidism at Maasstad Hospital Rotterdam in the Netherlands. Patients were instructed during 6 months to take 1 capsule in the morning and 1 capsule at bedtime (one containing

Full Text available with Trip Pro

2010 Archives of internal medicine

9. Effect of levothyroxine treatment on in vitro fertilization and pregnancy outcome in infertile women with subclinical hypothyroidism undergoing in vitro fertilization/intracytoplasmic sperm injection. (PubMed)

Effect of levothyroxine treatment on in vitro fertilization and pregnancy outcome in infertile women with subclinical hypothyroidism undergoing in vitro fertilization/intracytoplasmic sperm injection. To investigate whether levothyroxine (LT4) treatment has beneficial effects on IVF results and pregnancy outcome in infertile patients with subclinical hypothyroidism undergoing IVF/intracytoplasmic sperm injection (ICSI).Prospective, randomized trial.University-affiliated infertility clinic.A

2011 Fertility and sterility

10. Levothyrox (levothyroxine): a change in formulation results in thousands of reports of adverse effects

Levothyrox (levothyroxine): a change in formulation results in thousands of reports of adverse effects Prescrire IN ENGLISH - Spotlight ''Lévothyrox° (levothyroxine): a change in formulation results in thousands of reports of adverse effects'', 18 September 2017 {1} {1} {1} | | > > > Lévothyrox° (levothyroxine): a change in formulation results in thousands of reports of adverse effects Spotlight Every month, the subjects in Prescrire’s Spotlight. 100 most recent :  |   |    (...) |   |   |   |   |   |   |  Spotlight Lévothyrox° (levothyroxine): a change in formulation results in thousands of reports of adverse effects In France, the lactose in Lévothyrox° (levothyroxine) tablets was replaced by mannitol and citric acid was added as a preservative. According to France's national medicines agency (ANSM), two pharmacokinetics studies demonstrated that the old and the new tablets were bioequivalent. A pharmacovigilance

2017 Prescrire

11. Treatment with levothyroxin in subclinical hypothyroidism is associated with increased mortality in the elderly. (PubMed)

Treatment with levothyroxin in subclinical hypothyroidism is associated with increased mortality in the elderly. It is uncertain whether subclinical hypothyroidism should be treated with levothyroxine, particularly in the elderly. This study evaluated the association between levothyroxine treatment and mortality in individuals 65years or older with subclinical hypothyroidism and TSH values <10mIU/L.A case-control study in which patients 65years or older with TSH levels of 4.2-10mIU/L who died (...) in the years 2012-2016 ('cases') were compared with matched individuals who did not die during this period ('controls'). Matching was based on gender, age, Charlson comorbidity index, date of TSH testing, duration of follow-up and TSH quartile. All cases of known thyroid disease or cases in which anti-thyroid medications or glucocorticoids were dispensed in the year preceding the TSH evaluation were excluded. Use of levothyroxine was compared between groups.During the follow-up period, 419 individuals died

2017 European journal of internal medicine

12. Effects of Levothyroxine on pregnant women with subclinical hypothyroidism, negative for thyroid peroxidase antibodies. (PubMed)

Effects of Levothyroxine on pregnant women with subclinical hypothyroidism, negative for thyroid peroxidase antibodies. Currently, there is no consensus on universal thyroid screening and levothyroxine (LT4) treatment of pregnant women with subclinical hypothyroidism (SCH) who are negative for thyroid peroxidase antibody (TPOAb-).We aimed to evaluate the benefits of LT4 treatment on pregnancy outcomes in SCH-TPOAb- women.This study was conducted within the framework of the Tehran Thyroid

2017 Journal of Clinical Endocrinology and Metabolism

13. Quality of life, clinical outcomes and safety of early prophylactic levothyroxine administration in patients with Graves' hyperthyroidism undergoing radioiodine therapy: a randomized controlled study. (PubMed)

Quality of life, clinical outcomes and safety of early prophylactic levothyroxine administration in patients with Graves' hyperthyroidism undergoing radioiodine therapy: a randomized controlled study. While radioiodine therapy is commonly used for treating Graves' disease, a prolonged and clinical hypothyroidism may result in disabling symptoms leading to deterioration of quality of life (QoL) of patients. Introducing levothyroxine (LT4) treatment in the early post-therapeutic period may

Full Text available with Trip Pro

2016 European journal of endocrinology / European Federation of Endocrine Societies

14. A prospective randomized trial of levothyroxine suppressive therapy for solitary thyroid nodules. (PubMed)

A prospective randomized trial of levothyroxine suppressive therapy for solitary thyroid nodules. We examined the effects of L-thyroxine therapy versus placebo over a 12-month period on volume of solitary thyroid nodules.Prospective randomized clinical trial; placebo and control groups followed for one year in three centres.One hundred and one euthyroid patients with single palpable colloid thyroid nodules.Serum thyroid hormones, TSH, thyroglobulin, anti-thyroglobulin and anti-thyroid

1993 Clinical endocrinology

15. Sexual function and depressive symptoms in young women with hypothyroidism receiving levothyroxine/liothyronine combination therapy: a pilot study. (PubMed)

Sexual function and depressive symptoms in young women with hypothyroidism receiving levothyroxine/liothyronine combination therapy: a pilot study. Objective Even mild hypothyroidism in pre-menopausal women is accompanied by impaired sexual functioning. The study was aimed at comparing the effect of levothyroxine, administered alone or in combination with liothyronine, on sexual function and depressive symptoms in pre-menopausal women treated because of hypothyroidism. Methods This quasi (...) -randomized, single-blind study included 39 young women receiving levothyroxine treatment who, despite thyrotropin and thyroid hormone levels within normal limits, still experienced clinical symptoms of hypothyroidism. These patients were divided into two groups: group A (n = 20) continued levothyroxine treatment, while group B (n = 19) received levothyroxine/liothyronine combination therapy. At the beginning of the study, and 6 months later, all participants of the study filled in questionnaires

2018 Current medical research and opinion

16. Immunoallergic reactions with nifuroxazide; adverse effects of levothyroxine

Immunoallergic reactions with nifuroxazide; adverse effects of levothyroxine Prescrire IN ENGLISH - Spotlight ''In the November issue of Prescrire International: immunoallergic reactions with nifuroxazide; adverse effects of levothyroxine'', 1 November 2017 {1} {1} {1} | | > > > In the November issue of Prescrire International: immunoallergic reactions with nifuroxazide; adverse effects of levothyroxine Spotlight Every month, the subjects in Prescrire’s Spotlight. 100 most recent :  |  (...)  |   |   |   |   |   |   |   |  Spotlight In the November issue of Prescrire International: immunoallergic reactions with nifuroxazide; adverse effects of levothyroxine FREE DOWNLOAD This month's sample page from the Adverse Effects section demonstrates the wide range of information available every month in Prescrire International. Full text available for free download. Nifuroxazide: serious immunoallergic reactions Nifuroxazide is used

2017 Prescrire

17. Effect of Levothyroxine on Miscarriage Among Women With Normal Thyroid Function and Thyroid Autoimmunity Undergoing In Vitro Fertilization and Embryo Transfer: A Randomized Clinical Trial. (PubMed)

Effect of Levothyroxine on Miscarriage Among Women With Normal Thyroid Function and Thyroid Autoimmunity Undergoing In Vitro Fertilization and Embryo Transfer: A Randomized Clinical Trial. Presence of thyroid autoantibodies in women with normal thyroid function is associated with increased risk of miscarriage. Whether levothyroxine treatment improves pregnancy outcomes among women undergoing in vitro fertilization and embryo transfer (IVF-ET) is unknown.To determine the effect of levothyroxine (...) on miscarriage among women undergoing IVF-ET who had normal thyroid function and tested positive for thyroid autoantibodies.An open-label, randomized clinical trial involving 600 women who tested positive for the antithyroperoxidase antibody and were being treated for infertility at Peking University Third Hospital from September 2012 to March 2017.The intervention group (n = 300) received either a 25-μg/d or 50-μg/d dose of levothyroxine at study initiation that was titrated according to the level

Full Text available with Trip Pro

2017 JAMA

18. Switching from Liothyronine (LT-3) to Levothyroxine (LT-4)? Questions for GPs

Switching from Liothyronine (LT-3) to Levothyroxine (LT-4)? Questions for GPs The BTA is aware that some health authorities are advising GPs to switch patients on Liothyronine (L-T3) to Levothyroxine (L-T4). Whilst we appreciate the commercial imperative to cut prescription costs, like you, our first concern is that in all cases the clinical needs of the patient should come before financial considerations. This frequently asked questions (FAQS) sheet has been produced for GPs who (...) of avoiding under-replacement or over- replacement. The final L-T4 requirement is likely to be around 1.6mcg/kg. Any information about previous L-T4 dosage that achieved a normal serum TSH will be a Switching your patient from Liothyronine (L-T3) to Levothyroxine (L-T4)? Answering GP’s frequently asked questions useful guide. Gradual reduction of L-T3 starting at the same time as introducing or increasing L-T4 may be a preferable alternative. Careful monitoring of the patient by an endocrinologist during

2017 British Thyroid Association

19. Switching from Liothyronine (LT-3) to Levothyroxine (LT-4)? Information for Endocrinologists

Switching from Liothyronine (LT-3) to Levothyroxine (LT-4)? Information for Endocrinologists DECEMBER 2016 BRITISH THYROID ASSOCIATION EXECUTIVE COMMITTEE INFORMATION FOR MEMBERS ON PRESCRIBING LIOTHYRONINE (L-T3) The BTA Executive Committee have been made aware of recent difficulties encountered by patients in obtaining Liothyronine (L-T3). In some instances, patients who have long been established on L-T3 have had their treatment abruptly withdrawn and some clinicians have received requests (...) from local health authorities to switch patients from L-T3 to levothyroxine (L-T4). We are concerned that these actions are driven by cost considerations rather than clinical need and that the BTA position statement on the management of hypothyroidism is being inappropriately cited to support this requests. The BTA does not support the sudden withdrawal of L-T3 therapy and this practice does not in any way reflect our position statement. In this document we highlight current problems with L-T3

2017 British Thyroid Association

20. Clinical, behavioural and pharmacogenomic factors influencing the response to levothyroxine therapy in patients with diagnosed primary hypothyroidism

Clinical, behavioural and pharmacogenomic factors influencing the response to levothyroxine therapy in patients with diagnosed primary hypothyroidism Print | PDF PROSPERO This information has been provided by the named contact for this review. CRD has accepted this information in good faith and registered the review in PROSPERO. CRD bears no responsibility or liability for the content of this registration record, any associated files or external websites. Email salutation (e.g. "Dr Smith

2015 PROSPERO